Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹İstanbul Üniversitesi İstanbul Tıp Fakültesi, Göz Hastalıkları A.D., İstanbul, Asist. Dr.
²İstanbul Üniversitesi İstanbul Tıp Fakültesi, Göz Hastalıkları A.D., İstanbul, Uzm. Dr.
³İstanbul Üniversitesi İstanbul Tıp Fakültesi, Göz Hastalıkları A.D., İstanbul, Prof. Dr. Purpose: To evaluate visual acuity and foveal thickness alterations after intravitreal bevacizumab injection for macular edema due to retinal vein occlusion.
Material and Methods: Twenty-two eyes of 22 patients who underwent intravitreal bevacizumab injection for macular edema due to retinal vein occlusion were retrospectively analyzed. Single doze (1.25 mg/0.05 ml) bevacizumab (Avastin, Altuzan, Genantech,) injection was performed in every patient. Best corrected visual acuity (BCVA) and foveal thickness with OCT were evaluated before and 1, 3, 6 months after injection.
Results: The mean follow-up time was 8.64±2.4 (6-14) months. The mean preinjection BCVA was 1.21±0.41.The mean BCVA 1, 3 and 6 months after injections were 0.72±0.21, 0.73±0.23, 0.94±0.24, logMAR. respectively. The mean preinjection foveal thickness was 495±125 μm.The mean Foveal thickness 1, 3 and 6 months afterinjections were 279±75 μm, 297±83 μm, 345±91 μm respectively.The improvements in BCVA and foveal thickness at 1 and 3 months after injection were statistically significant compared to preinjection values.
Conclusion: the efficiency of single dose iv bevacizumab injection for macular edema due to retinal vein occlusion was maximum at 1 month. The efficiency decreased after 1 months. Keywords : Vein occlusion, bevacizumab, intravitreal injection